These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Capped antithrombin III dosing is cost effective in the management of asparaginase-associated thrombosis.
    Author: Young J, Sawyer J, Jenkins M, O'Brien M, Luchtman-Jones L, Breese EH.
    Journal: Pediatr Blood Cancer; 2019 Jun; 66(6):e27719. PubMed ID: 30900794.
    Abstract:
    Asparaginase therapy induces a transient antithrombin III (ATIII) deficiency, which contributes to the risk of asparaginase-induced thrombosis. At Cincinnati Children's Hospital Medical Center, management of asparaginase-induced thrombosis includes ATIII supplementation during therapeutic anticoagulation with enoxaparin. Due to the expense associated with ATIII, a capped dosing approach for ATIII was evaluated in this population. Peak ATIII levels were obtained following capped doses to evaluate response. In this pilot evaluation, 11 patients received a total of 138 capped doses for a total cost savings of $803 782. This pilot evaluation represents the first reported analysis of capped ATIII dosing in oncology patients.
    [Abstract] [Full Text] [Related] [New Search]